A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Brodalumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 21 Apr 2015 According to media release, status changed from recruiting to discontinued.
    • 23 Nov 2014 Planned End Date changed from 1 Feb 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.
    • 23 Nov 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top